Ignite Creation Date:
2025-12-24 @ 4:01 PM
Ignite Modification Date:
2026-02-01 @ 11:10 PM
Study NCT ID:
NCT03066466
Status:
WITHDRAWN
Last Update Posted:
2021-04-27
First Post:
2017-02-23
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D015470', 'term': 'Leukemia, Myeloid, Acute'}, {'id': 'D054198', 'term': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma'}, {'id': 'D009190', 'term': 'Myelodysplastic Syndromes'}, {'id': 'D006086', 'term': 'Graft vs Host Disease'}], 'ancestors': [{'id': 'D007951', 'term': 'Leukemia, Myeloid'}, {'id': 'D007938', 'term': 'Leukemia'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D006402', 'term': 'Hematologic Diseases'}, {'id': 'D006425', 'term': 'Hemic and Lymphatic Diseases'}, {'id': 'D007945', 'term': 'Leukemia, Lymphoid'}, {'id': 'D008232', 'term': 'Lymphoproliferative Disorders'}, {'id': 'D008206', 'term': 'Lymphatic Diseases'}, {'id': 'D007160', 'term': 'Immunoproliferative Disorders'}, {'id': 'D007154', 'term': 'Immune System Diseases'}, {'id': 'D001855', 'term': 'Bone Marrow Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000069059', 'term': 'Atorvastatin'}, {'id': 'D008727', 'term': 'Methotrexate'}, {'id': 'D016559', 'term': 'Tacrolimus'}], 'ancestors': [{'id': 'D011758', 'term': 'Pyrroles'}, {'id': 'D001393', 'term': 'Azoles'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D006538', 'term': 'Heptanoic Acids'}, {'id': 'D005227', 'term': 'Fatty Acids'}, {'id': 'D008055', 'term': 'Lipids'}, {'id': 'D000630', 'term': 'Aminopterin'}, {'id': 'D011622', 'term': 'Pterins'}, {'id': 'D011621', 'term': 'Pteridines'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D018942', 'term': 'Macrolides'}, {'id': 'D007783', 'term': 'Lactones'}, {'id': 'D009930', 'term': 'Organic Chemicals'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'PREVENTION', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Randomized, two arms'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 0}}, 'statusModule': {'whyStopped': 'No participants were enrolled', 'overallStatus': 'WITHDRAWN', 'startDateStruct': {'date': '2019-12-10', 'type': 'ESTIMATED'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2021-04', 'completionDateStruct': {'date': '2021-02-28', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2021-04-23', 'studyFirstSubmitDate': '2017-02-23', 'studyFirstSubmitQcDate': '2017-02-23', 'lastUpdatePostDateStruct': {'date': '2021-04-27', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2017-02-28', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2020-02-28', 'type': 'ESTIMATED'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'To determine the effect of atorvastatin on immune reconstitution', 'timeFrame': '2 years', 'description': 'Blood work will be used to evaluate recovery of white blood cells, red blood cells and platelets plus T and B cell count subset.'}], 'primaryOutcomes': [{'measure': 'The primary objective is to determine the cumulative incidence of chronic GVHD at one year after stem cell transplantation and treatment with atorvastatin', 'timeFrame': '2 years', 'description': 'National Institutes of Health Chronic Graft-Versus-Host Disease Grading and Form'}], 'secondaryOutcomes': [{'measure': 'To determine the cumulative incidence of grade 3 to 4 acute GVHD', 'timeFrame': '100 days', 'description': 'National Institutes of Health Acute Graft-Versus-Host Disease Grading and Form'}, {'measure': 'To determine rate of disease relapse', 'timeFrame': '2 years', 'description': 'Blood work and/or bone marrow biopsy will be used'}, {'measure': 'To determine non-relapse mortality (NRM)', 'timeFrame': '2 years', 'description': 'Blood work and/or bone marrow biopsy will be used'}, {'measure': 'To determine progression-free survival (PFS)', 'timeFrame': '2 years', 'description': 'Blood work and/or bone marrow biopsy will be used'}, {'measure': 'To determine overall survival (OS)', 'timeFrame': '2 years', 'description': 'Blood work and/or bone marrow biopsy will be used'}, {'measure': 'Number of participants with Grade 4 through 5 Adverse Events that are related to study treatment, grading according to NCI CTCAE Version 4', 'timeFrame': '30 days of the last dose of protocol treatment', 'description': 'Toxicities that are possibly, probably, and definitely related'}, {'measure': 'Determine the frequency and severity of chronic GVHD', 'timeFrame': '2 years', 'description': 'National Institutes of Health Chronic Graft-Versus-Host Disease Grading and Form'}]}, 'oversightModule': {'isUsExport': False, 'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Acute Myeloid Leukemia', 'Acute Lymphocytic Leukemia', 'Myelodysplastic Syndrome', 'BMT', 'Matched unrelated donor transplant', 'Graft versus Host Disease', 'GVHD'], 'conditions': ['Acute Myeloid Leukemia', 'Acute Lymphocytic Leukemia', 'Myelodysplastic Syndrome']}, 'descriptionModule': {'briefSummary': 'Chronic Graft Versus Host Disease (GVHD) is one of the most challenging complications in long term survivors of allogeneic stem cell transplantation. As the number of allogeneic stem cell transplantations rises annually, the incidence of chronic GVHD rates have also increased due to a variety of factors including but not limited to increasing use of peripheral blood stem cell (PBSC) grafts, increasing age of both donors and recipients, and increased use of matched unrelated donors. One study showed much lower than traditional acute GHVD rate and chronic GHVD which is similar with historical rates when atorvastatin was administered prophylactically to both the donors as well as recipients of matched related allogeneic stem cell transplantation, lead to the interest in further examining the role of Atorvastatin in relation to the development of GVHD. The investigator hypothesize that the administration of atorvastatin in recipients of matched unrelated allogeneic stem cell transplantation, a group with known higher incidence of chronic GHVD, would be a safe and effective method to reduce the incidence of chronic GVHD. Matched related allogeneic stem cell transplantation recipients will not be included in this study due to their significantly lower GVHD rates. The definition and monitoring of our primary endpoint of GVHD is well established in clinical trials in allogeneic stem cell transplantations and the investiagor will utilize the National Institutes of Health (NIH) Staging System for the diagnosis and severity assessment of chronic GVHD as well the recommendations from the NIH Consensus Conference for the conduct of clinical trials in chronic GVHD.\n\nSeveral secondary endpoints will be examined as defined below and include standard complementary data in the examination of clinical trials in chronic GVHD again as laid out by the NIH Consensus Conference for conduct of clinical trials in chronic GHVD.', 'detailedDescription': "This is a randomized, open label phase III trial in patients with Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, and Myelodysplastic Syndrome undergoing matched unrelated donor transplant.\n\nPatients randomized to the treatment arm (atorvastatin):\n\nThe prophylaxis atorvastatin treatment (taken by mouth) for GVHD will start at 14 days prior to transplant and continue until 365 days post-transplant or until development of significant adverse events or desire of the primary treating physician to stop the administration.\n\nThe patients will also receive our institution's standard graft versus host disease prophylactic regimen which consists of two drugs. It has been shown that immunosuppression with two drugs is better than a single agent thus our institution utilizes a combination of Methotrexate and Tacrolimus. For all matched unrelated donor allogeneic transplantation patients, the following schedule of Methotrexate will be administered intravenously (IV) post-transplant on Days 1, 3 and 6. Tacrolimus will be administered 2 days prior to transplant and continue approximately 180 days post-transplant. Tacrolimus will be administered IV until patient can take it by mouth.\n\nPatients randomized to standard of care:\n\nPatients will receive our institution's standard graft versus host disease prophylactic regimen which consists of two drugs. It has been shown that immunosuppression with two drugs is better than a single agent thus our institution utilizes a combination of Methotrexate and Tacrolimus. For all matched unrelated donor allogeneic transplantation patients, the following schedule of Methotrexate will be administered intravenously (IV) post-transplant on Days 1, 3 and 6. Tacrolimus will be administered 2 days prior to transplant and continue approximately 180 days post-transplant. Tacrolimus will be administered IV until patient can take it by mouth."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '75 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria\n\n* Men or women between 18-65 years of age\n* Patients designated to undergo allogeneic peripheral blood or bone marrow stem cell transplantation from matched unrelated donor following the diagnosis of one of the following primary diseases in early or intermediate disease status:\n\n * AML at the following stages at time of screening: 1st remission, 2nd remission, and 3rd or subsequent remission\n * ALL at the following stages at time of screening: 1st remission, 2nd remission, and 3rd or subsequent remission\n * MDS\n* Patients must have Performance Score (PS) greater than 70 percent\n\nExclusion Criteria\n\n* Cardiac: ejection fraction less than 40 percent or other significant cardiac disease\n* Pulmonary: FEV1 or DLCO less than 45 percent\n* Renal: creatinine greater than the upper limit of normal\n* Hepatic: bilirubin greater than 2.0 times the upper limit of normal\n* CNS: documented active CNS disease\n* Patients who are known to be positive for Hepatitis B surface antigen or Hepatitis C antibody, or who have tested positive for HIV'}, 'identificationModule': {'nctId': 'NCT03066466', 'briefTitle': 'Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT', 'organization': {'class': 'OTHER', 'fullName': 'Loyola University'}, 'officialTitle': 'Randomized Study of Atorvastatin Prophylaxis as a Supplement to Standard of Care Prophylaxis to Prevent Chronic Graft Versus Host Disease Allogeneic Stem Cell Transplantation From Matched Unrelated Donors', 'orgStudyIdInfo': {'id': '208106'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Arm A: Atorvastatin', 'description': 'The preventative atorvastatin treatment 40mg daily by mouth for GVHD will start at 14 days prior to transplant \\& continue until 365 days post-transplant or if significant adverse events occur. Patients will also receive our standard of care for graft versus host disease prevention which consists of two drugs, Methotrexate and Tacrolimus. For all matched unrelated donor allogeneic transplantation patients, the following schedule of Methotrexate 5mg/metered square will be administered IV post-transplant on Days 1, 3 \\& 6. Tacrolimus will be administered 2 days prior to transplant \\& continue approximately 180 days post-transplant. Tacrolimus 0.03 mg/kg daily will be administered IV until patient can take it by mouth.', 'interventionNames': ['Drug: Atorvastatin', 'Drug: Methotrexate', 'Drug: Tacrolimus']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Arm B: Standard of Care', 'description': 'Patients will receive our standard of care for graft versus host disease prevention which consists of two drugs, Methotrexate and Tacrolimus. For all matched unrelated donor allogeneic transplantation patients, the following schedule of Methotrexate 5mg/metered square will be administered IV post-transplant on Days 1, 3 \\& 6. Tacrolimus will be administered 2 days prior to transplant \\& continue approximately 180 days post-transplant. Tacrolimus 0.03 mg/kg daily will be administered IV until patient can take it by mouth.', 'interventionNames': ['Drug: Methotrexate', 'Drug: Tacrolimus']}], 'interventions': [{'name': 'Atorvastatin', 'type': 'DRUG', 'otherNames': ['Lipitor'], 'description': 'Oral medication given to prevent graft versus host disease in bone marrow transplant.', 'armGroupLabels': ['Arm A: Atorvastatin']}, {'name': 'Methotrexate', 'type': 'DRUG', 'otherNames': ['Trexall'], 'description': 'IV medication given to prevent graft versus host disease in bone marrow transplant.', 'armGroupLabels': ['Arm A: Atorvastatin', 'Arm B: Standard of Care']}, {'name': 'Tacrolimus', 'type': 'DRUG', 'otherNames': ['Prograft'], 'description': 'IV or Oral medication given to prevent graft versus host disease in bone marrow transplant.', 'armGroupLabels': ['Arm A: Atorvastatin', 'Arm B: Standard of Care']}]}, 'contactsLocationsModule': {'locations': [{'zip': '60153', 'city': 'Maywood', 'state': 'Illinois', 'country': 'United States', 'facility': 'Loyola University Medical Center', 'geoPoint': {'lat': 41.8792, 'lon': -87.84312}}], 'overallOfficials': [{'name': 'Patrick Stiff, MD', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Cardinal Bernardin Cancer Center, Loyola University'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Loyola University', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Professor', 'investigatorFullName': 'Patrick Stiff', 'investigatorAffiliation': 'Loyola University'}}}}